Mersana Therapeutics
Yahoo Finance • 2 months ago
Mersana targets reporting initial Emi-Le expansion data in H2 2025 while achieving $15M GSK milestone
Earnings Call Insights: Mersana Therapeutics (MRSN) Q2 2025 MANAGEMENT VIEW * Martin H. Huber, President, CEO & Director, opened by highlighting the progress on Emi-Le, the company's Dolasynthen ADC targeting B7-H4, emphasizing oral pr... Full story
Yahoo Finance • 2 months ago
Mersana Therapeutics Q2 2025 Earnings Preview
* Mersana Therapeutics (NASDAQ:MRSN [https://seekingalpha.com/symbol/MRSN]) is scheduled to announce Q2 earnings results on Wednesday, August 13th, before market open. The consensus EPS Estimate is -$4.25 [https://seekingalpha.com/symbo... Full story
Yahoo Finance • 2 months ago
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high un... Full story
Yahoo Finance • 3 months ago
Mersana To Implement 1-for-25 Reverse Stock Split To Regain Nasdaq Compliance
(RTTNews) - Mersana Therapeutics (MRSN) will implement a 1-for-25 reverse stock split effective July 25, 2025, aiming to boost its share price and regain compliance with Nasdaq's minimum bid requirement. Approved by shareholders on June 1... Full story
Yahoo Finance • 3 months ago
Mersana Therapeutics Announces 1-for-25 Reverse Stock Split
CAMBRIDGE, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high un... Full story
Yahoo Finance • 4 months ago
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., J... Full story
Yahoo Finance • 5 months ago
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high u... Full story
Yahoo Finance • 5 months ago
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
Cost-saving initiatives expected to extend company’s cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 fin... Full story
Yahoo Finance • 6 months ago
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting canc... Full story
Yahoo Finance • 6 months ago
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cance... Full story
Yahoo Finance • 6 months ago
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting canc... Full story
Yahoo Finance • 7 months ago
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously treated with at least one topoisomerase-1... Full story
Yahoo Finance • 8 months ago
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cance... Full story
Yahoo Finance • 8 months ago
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cance... Full story
Yahoo Finance • 2 years ago
15 Small-Cap Stocks with High Potential
In this article, we will take a look at the 15 small-cap stocks with high potential. To skip our analysis of the latest trends, and market activity, you can go directly to see the 5 Small-Cap Stocks with High Potential. Nearly 9,500 stock... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics Inc (MRSN) Reports Q3 2023 Financial Results
Mersana Therapeutics Inc (NASDAQ:MRSN) released its Q3 2023 financial results on November 7, 2023. The company reported a net loss of $41.6 million for the quarter, compared to a net loss of $59.8 million in Q3 2022. Collaboration revenue... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results
Advancing dose escalation portion of Phase 1 clinical trial of XMT-1660, Mersana’s B7-H4 Dolasynthen ADCPreparations underway to resume enrollment in Phase 1 clinical trial of XMT-2056, Mersana’s HER2 Immunosynthen ADCCapital resources exp... Full story
Yahoo Finance • 2 years ago
Mersana Therapeutics Announces Changes in Leadership
Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chie... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSN
NEW YORK, July 09, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mersana Therapeutics, Inc. (“Mersana” or the “Company”) (NASDAQ: MRSN). Such investors are advised to contact Robert S. Willoug... Full story
